This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).
Thierry Passeron, MD, PhD
Advertisement
Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.
Articles by Thierry Passeron, MD, PhD
In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).
Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: GLP-1 Receptor Agonists and the Advent of CKM Syndrome, With Lawrence Leiter, MD
2
The HCPFive: Top News for Healthcare Providers from the Week of 06/21
3
Expanding Use of Dupilumab in Pediatric Patients, With Ilona Frieden, MD
4
When the Allergen Is Not What You Expected: 2 Contact Dermatitis Cases
5